| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
9,610,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.72 - $0.72 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Edesa Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for inflammatory and immune-related diseases. Co.'s primary product candidates include: EB05, which is a monoclonal antibody therapy for the treatment for Acute Respiratory Distress Syndrome in COVID-19 patients; and EB01, which is a secretory phospholipase 2 (sPLA2) inhibitor for the topical treatment for chronic allergic contact dermatitis, a potentially debilitating condition and occupational illness. Co.'s EB02 drug candidate represents a potential extension of its sPLA2 anti-inflammatory technology. Co.'s product candidate EB06, is a monoclonal antibody candidate.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
5,000 |
5,000 |
5,000 |
41,500 |
| Total Buy Value |
$20,000 |
$20,000 |
$20,000 |
$80,667 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
1 |
7 |
| Total Shares Sold |
0 |
0 |
0 |
297,474 |
| Total Sell Value |
$0 |
$0 |
$0 |
$787,716 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2022-03-18 |
4 |
B |
$3.85 |
$7,699 |
D/D |
2,000 |
561,812 |
0.01 |
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2022-03-17 |
4 |
B |
$3.25 |
$6,522 |
D/D |
2,000 |
559,812 |
0.01 |
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2022-03-15 |
4 |
B |
$2.80 |
$5,598 |
D/D |
2,000 |
557,812 |
0.01 |
- |
|
| Brooks Michael J |
President |
• – – |
2022-03-14 |
4 |
B |
$2.79 |
$3,487 |
D/D |
1,250 |
16,741 |
0.01 |
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2022-03-11 |
4 |
B |
$3.06 |
$21,652 |
D/D |
7,000 |
555,812 |
0.01 |
- |
|
| Brooks Michael J |
President |
• • – |
2022-03-10 |
4 |
B |
$3.22 |
$3,223 |
D/D |
1,000 |
15,491 |
0.01 |
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2022-03-09 |
4 |
B |
$3.05 |
$4,570 |
D/D |
1,500 |
548,812 |
0.01 |
- |
|
| Brooks Michael J |
President |
• • – |
2022-03-08 |
4 |
B |
$2.90 |
$3,622 |
D/D |
1,250 |
14,491 |
0.01 |
- |
|
| Brooks Michael J |
President |
• • – |
2021-03-25 |
4 |
B |
$5.19 |
$18,165 |
D/D |
3,500 |
13,241 |
0.01 |
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2021-03-25 |
4 |
B |
$5.25 |
$15,750 |
D/D |
3,000 |
545,312 |
0.01 |
- |
|
| Brooks Michael J |
President |
• • – |
2021-03-24 |
4 |
B |
$5.08 |
$22,860 |
D/D |
4,500 |
9,741 |
0.01 |
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2021-03-24 |
4 |
B |
$5.16 |
$25,800 |
D/D |
5,000 |
542,312 |
0.01 |
- |
|
| Oakes Frank R. |
|
• • – |
2021-02-18 |
4 |
S |
$7.25 |
$44,696 |
D/D |
(6,165) |
0 |
|
- |
|
| Oakes Frank R. |
|
• • – |
2021-02-18 |
4 |
S |
$7.25 |
$13,246 |
I/I |
(1,827) |
0 |
|
- |
|
| Johnson Lorin K |
|
• • – |
2020-11-09 |
4 |
OE |
$4.00 |
$17,048 |
D/D |
4,262 |
12,786 |
|
- |
|
| Pay Paul William |
|
• • – |
2020-11-06 |
4 |
OE |
$4.00 |
$4,872 |
D/D |
1,218 |
3,654 |
|
- |
|
| Brooks Michael J |
President |
• • – |
2020-11-06 |
4 |
OE |
$4.00 |
$3,656 |
D/D |
914 |
5,241 |
|
- |
|
| Niffenegger Kathi |
Chief Financial Officer |
• • – |
2020-11-06 |
4 |
OE |
$4.00 |
$2,436 |
I/I |
609 |
1,827 |
|
- |
|
| Sistilli Carlo |
|
• • – |
2020-11-05 |
4 |
OE |
$4.00 |
$4,872 |
I/I |
1,218 |
3,654 |
|
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2020-11-05 |
4 |
OE |
$4.00 |
$18,512 |
I/I |
4,628 |
2,128,652 |
|
- |
|
| Lumira Capital Investment Management Inc. |
|
• • • |
2020-11-02 |
4 |
OE |
$4.00 |
$281,256 |
I/I |
70,314 |
175,454 |
|
- |
|
| Oakes Frank R. |
|
• • – |
2020-10-06 |
4 |
OE |
$4.00 |
$2,436 |
I/I |
609 |
1,827 |
|
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2020-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
371,727 |
371,727 |
|
- |
|
| Brooks Michael J |
President |
• • – |
2020-05-27 |
4 |
B |
$3.00 |
$7,499 |
D/D |
2,500 |
4,327 |
0.01 |
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2020-05-26 |
4 |
B |
$2.98 |
$8,939 |
I/I |
3,000 |
2,124,024 |
0.01 |
- |
|
95 Records found
|
|
Page 2 of 4 |
|
|
